Reset filters
  • 13 April 2007

Is there any clinical benefit to staying on a failing regimen?

Read the article
  • 5 April 2007

Darunavir looking promising as companion for agents in new HIV drug classes

Read the article
  • 19 March 2007

Next generation NRTI, apricitabine (ATC), shows early promise

Read the article
  • 6 March 2007

CROI: Experimental 'salvage' integrase inhibitor, elvitegravir (GS-9137) appears potent at higher doses

Read the article
  • 28 February 2007

CROI: Maraviroc shows potent effect in highly treatment-experienced

Read the article
  • 28 February 2007

CROI: Integrase inhibitor raltegravir (MK-0518) doubles HIV suppression in treatment-experienced patients at 16 weeks

Read the article
  • 21 December 2006

After 48 weeks of study, and 24 weeks in the real world, darunavir continues to show staying power

Read the article
  • 15 December 2006

Prezista (darunavir) approved for treatment-experienced patients in Europe

Read the article
  • 30 November 2006

Pfizer announces expanded access programme for maraviroc

Read the article

Receive the latest HIV research and conference news

Complete this form to receive regular email bulletins including the latest HIV research and conference news from aidsmap and/or updates from Terrence Higgins Trust.

Get regular email bulletins

Please let us know how you'd like to be contacted by ticking the options below.